Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
Spero Therapeutics, Inc. (SPRO)
Today's Latest Price: $12.13 USD
Updated Jun 4 6:55pm
Add SPRO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SPRO Stock Summary
- Spero Therapeutics Inc's stock had its IPO on November 2, 2017, making it an older stock than merely 7.75% of US equities in our set.
- Of note is the ratio of Spero Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 8.49% of US stocks have a lower such ratio.
- With a price/sales ratio of 20.6, Spero Therapeutics Inc has a higher such ratio than 93.44% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Spero Therapeutics Inc, a group of peers worth examining would be AFMD, GRTS, TLC, ACIU, and UMRX.
- SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.
SPRO Stock Price Chart More Charts
SPRO Price/Volume Stats
| Current price | $12.13 | 52-week high | $14.38 |
| Prev. close | $12.32 | 52-week low | $5.25 |
| Day low | $11.92 | Volume | 139,900 |
| Day high | $12.71 | Avg. volume | 132,350 |
| 50-day MA | $10.21 | Dividend yield | N/A |
| 200-day MA | $10.11 | Market Cap | 249.82M |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Loading social stream, please wait...